Kathy Y Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5976002/publications.pdf Version: 2024-02-01



ΚΛΤΗΥΥΙΙΙΙ

#	Article	IF	CITATIONS
1	Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain, 2019, 142, 2558-2571.	7.6	219
2	Magnetic resonance imaging of the human locus coeruleus: A systematic review. Neuroscience and Biobehavioral Reviews, 2017, 83, 325-355.	6.1	124
3	InÂvivo visualization of age-related differences in the locus coeruleus. Neurobiology of Aging, 2019, 74, 101-111.	3.1	117
4	Questions EMERGE as Biogen claimsÂaducanumab turnaround. Nature Reviews Neurology, 2020, 16, 63-64.	10.1	98
5	Noradrenergic-dependent functions are associated with age-related locus coeruleus signal intensity differences. Nature Communications, 2020, 11, 1712.	12.8	74
6	Can we learn lessons from the FDA's approval of aducanumab?. Nature Reviews Neurology, 2021, 17, 715-722.	10.1	66
7	The need to show minimum clinically important differences in Alzheimer's disease trials. Lancet Psychiatry,the, 2021, 8, 1013-1016.	7.4	60
8	Dementia wellbeing and COVIDâ€19: Review and expert consensus on current research and knowledge gaps. International Journal of Geriatric Psychiatry, 2021, 36, 1597-1639.	2.7	52
9	Prevalence, management, and outcomes of SARS-CoV-2 infections in older people and those with dementia in mental health wards in London, UK: a retrospective observational study. Lancet Psychiatry,the, 2020, 7, 1054-1063.	7.4	48
10	Heart rate variability in relation to cognition and behavior in neurodegenerative diseases: A systematic review and meta-analysis. Ageing Research Reviews, 2022, 73, 101539.	10.9	32
11	The neurochemistry of agitation in Alzheimer's disease: a systematic review. Ageing Research Reviews, 2018, 43, 99-107.	10.9	31
12	Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer's disease: systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1080-1090.	1.9	24
13	Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimer's disease. Brain, 2020, 143, 3842-3849.	7.6	17
14	Acute mental health presentations before and during the COVID-19 pandemic. BJPsych Open, 2021, 7, e134.	0.7	16
15	The Relationship Between Anxiety and Incident Agitation in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 78, 1119-1127.	2.6	9
16	Towards safer risperidone prescribing in Alzheimer's disease. British Journal of Psychiatry, 2021, 218, 268-275.	2.8	9
17	FDG-PET assessment of the locus coeruleus in Alzheimer's disease. NeuroImage Reports, 2021, 1, 100002.	1.0	9
18	Pharmacological treatment trials of agitation in Alzheimer's disease: A systematic review of ClinicalTrials.gov registered trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12157.	3.7	6

Kathy Y Liu

#	Article	IF	CITATIONS
19	Frailty and dementia: what can the body tell us about the brain?. International Psychogeriatrics, 2021, 33, 1001-1003.	1.0	1
20	Pimavanserin and dementia-related psychosis: can HARMONY prevail?. Lancet Neurology, The, 2021, 20, 783-784.	10.2	1
21	Why has adult hippocampal neurogenesis had so little impact on psychiatry?. British Journal of Psychiatry, 2018, 212, 193-194.	2.8	0
22	Functional indicators of a decline in the noradrenergic locus coeruleus in ageing. Alzheimer's and Dementia, 2020, 16, e044582.	0.8	0
23	Infection control and the prevalence, management and outcomes of SARS-CoV-2 infections in mental health wards in London, UK: lessons learned from wave 1 to wave 2. BJPsych Open, 2022, 8, e63.	0.7	0